A. Ultra-long–acting insulin products have a duration of action of up to 42 hours. B. Glargine U-300 is an ultra-long–acting insulin product. C. Ultra-long–acting insulin products are not yet available as combination products. D. Ultra-long–acting insulin products have a slower onset of action compared to long-acting–insulin products.

A. 1 unit B. 2 units C. Priming varies depending on the amount to be injected and the type of insulin being used. D. Priming is no longer recommended.

A. Provide all education up front and then test the patient at the end of the visit using an American Diabetes Association-approved quiz. B. Ask the patient “Do you understand?”after each teaching point. C. Ask the patient what drives them most crazy about having diabetes. D. Ask the patient to teach back what they learned throughout the visit.

A. Lack of perceived value B. Lack of motivation to live a long and healthy life C. Fear of hypoglycemia D. Depression

A. Using EARS: Explore with open-ended questions, Affirm, Reflect, and Sum up B. Using NOSE: Nod frequently to acknowledge the patient, Outline the key educational points, Summarize, and Extend patient education via follow up visits C. Using the techniques of Collaboration, Conjuration, and Constancy D. Using the Stages of Change quiz

A. Refer her to the insulin manufacturer's Web site for enrollment in their drug assistance program. B. Recommend that SJ call her physician to ask for a medication that will not cause weight gain. C. Ask SJ, “On a scale of 0 to 10, where 0 is not at all important, and 10 is very important, how important is it for you to improve your diabetes?” D. Suggest that SJ start weighing herself every week, and give her a copy of the American Diabetes Association's recommendations for diabetes management.